Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 9.12
(-0.44%)
CNY 9.12
(-0.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 138.32 Million CNY | -42.43% |
| 2022 | 297.1 Million CNY | -31.86% |
| 2021 | 435.98 Million CNY | -27.78% |
| 2020 | 603.71 Million CNY | 3.43% |
| 2019 | 583.7 Million CNY | 34.68% |
| 2018 | 433.41 Million CNY | 18.42% |
| 2017 | 365.98 Million CNY | 12.1% |
| 2016 | 326.47 Million CNY | 58.75% |
| 2015 | 205.65 Million CNY | 47.47% |
| 2014 | 139.45 Million CNY | 21.5% |
| 2013 | 114.78 Million CNY | 23.39% |
| 2012 | 93.02 Million CNY | 13.09% |
| 2011 | 82.25 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 25.9 Million CNY | 33.35% |
| 2024 Q1 | 51.51 Million CNY | 95.53% |
| 2024 Q2 | 19.42 Million CNY | -62.3% |
| 2023 Q3 | 61.78 Million CNY | 49.93% |
| 2023 FY | 171.05 Million CNY | -42.43% |
| 2023 Q1 | 41.71 Million CNY | -34.85% |
| 2023 Q4 | 26.34 Million CNY | -57.35% |
| 2023 Q2 | 41.2 Million CNY | -1.22% |
| 2022 Q2 | 69.19 Million CNY | -29.86% |
| 2022 Q3 | 65.22 Million CNY | -5.74% |
| 2022 Q4 | 64.03 Million CNY | -1.83% |
| 2022 FY | 297.1 Million CNY | -31.86% |
| 2022 Q1 | 98.65 Million CNY | 2.66% |
| 2021 Q1 | 142.9 Million CNY | 21.6% |
| 2021 Q2 | 130.43 Million CNY | -8.73% |
| 2021 Q4 | 96.09 Million CNY | 44.39% |
| 2021 FY | 435.98 Million CNY | -27.78% |
| 2021 Q3 | 66.55 Million CNY | -48.97% |
| 2020 Q3 | 125.24 Million CNY | -39.57% |
| 2020 Q1 | 153.66 Million CNY | -11.22% |
| 2020 Q4 | 117.52 Million CNY | -6.16% |
| 2020 FY | 603.71 Million CNY | 3.43% |
| 2020 Q2 | 207.27 Million CNY | 34.89% |
| 2019 Q1 | 104.44 Million CNY | 23.03% |
| 2019 Q4 | 173.08 Million CNY | -0.8% |
| 2019 FY | 583.7 Million CNY | 34.68% |
| 2019 Q3 | 174.47 Million CNY | 32.48% |
| 2019 Q2 | 131.7 Million CNY | 26.1% |
| 2018 Q3 | 101.71 Million CNY | -20.19% |
| 2018 FY | 433.41 Million CNY | 18.42% |
| 2018 Q4 | 84.89 Million CNY | -16.54% |
| 2018 Q2 | 127.44 Million CNY | 6.77% |
| 2018 Q1 | 119.36 Million CNY | 27.7% |
| 2017 Q3 | 83.91 Million CNY | -11.45% |
| 2017 Q2 | 94.76 Million CNY | 1.0% |
| 2017 Q4 | 93.47 Million CNY | 11.39% |
| 2017 FY | 365.98 Million CNY | 12.1% |
| 2017 Q1 | 93.83 Million CNY | 9.39% |
| 2016 FY | 326.47 Million CNY | 58.75% |
| 2016 Q1 | 70.12 Million CNY | 14.79% |
| 2016 Q3 | 88.35 Million CNY | 7.47% |
| 2016 Q4 | 85.77 Million CNY | -2.92% |
| 2016 Q2 | 82.21 Million CNY | 17.24% |
| 2015 Q2 | 49.09 Million CNY | 20.96% |
| 2015 Q4 | 61.09 Million CNY | 11.31% |
| 2015 Q3 | 54.88 Million CNY | 11.79% |
| 2015 Q1 | 40.58 Million CNY | 13.4% |
| 2015 FY | 205.65 Million CNY | 47.47% |
| 2014 FY | 139.45 Million CNY | 21.5% |
| 2014 Q1 | 30.01 Million CNY | 0.0% |
| 2014 Q4 | 35.79 Million CNY | 0.0% |
| 2013 FY | 114.78 Million CNY | 23.39% |
| 2012 FY | 93.02 Million CNY | 13.09% |
| 2011 FY | 82.25 Million CNY | 0.0% |